Douglas S Goodin

List of Publications by Year
in descending order

#	Article	IF	Citations
1	Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS) Tj ETQq1 1 0.784314 rgBT /Overlo 545-556.	10.2	707
2	Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosis. Human Molecular Genetics, 2009, 18, 767-778.	2.9	419
3	250 Î¼g or 500 Î¼g interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurology, The, 2009, 8, 889-897.	10.2	377
4	Longâ€term evolution of multiple sclerosis disability in the treatment era. Annals of Neurology, 2016, 80, 499-510.	5.3	331
5	Mapping Multiple Sclerosis Susceptibility to the HLA-DR Locus in African Americans. American Journal of Human Genetics, 2004, 74, 160-167.	6.2	311
6	Silent progression in disease activityâ€"free relapsing multiple sclerosis. Annals of Neurology, 2019, 85, 653-666.	5.3	265
7	Mortality in patients with multiple sclerosis. Neurology, 2013, 81, 184-192.	1.1	199
8	The Causal Cascade to Multiple Sclerosis: A Model for MS Pathogenesis. PLoS ONE, 2009, 4, e4565.	2.5	192
9	Electrophysiological dfierences between demented and nondemented patients with Parkinson's disease. Annals of Neurology, 1987, 21, 90-94.	5.3	153
10	Magnetic resonance imaging in amyotrophic lateral sclerosis. Annals of Neurology, 1988, 23, 418-420.	5.3	137
11	The epidemiology of multiple sclerosis. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2014, 122, 231-266.	1.8	136
12	Association of Vitamin D Levels With Multiple Sclerosis Activity and Progression in Patients Receiving Interferon Beta-1b. JAMA Neurology, 2015, 72, 1458.	9.0	130
13	Magnetic resonance imaging as a surrogate outcome measure of disability in multiple sclerosis: Have we been overly harsh in our assessment?. Annals of Neurology, 2006, 59, 597-605.	5.3	103
14	Dermatomal somatosensory evoked potentials unilateral lumbosacral radiculopathy. Annals of Neurology, 1985, 17, 171-176.	5.3	94
15	An Early Eventâ€Related Cortical Potential. Psychophysiology, 1978, 15, 360-365.	2.4	87
16	Relationship between early clinical characteristics and long term disability outcomes: 16 year cohort study (follow-up) of the pivotal interferon Î²-1b trial in multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, 282-287.	1.9	87
17	A comparison of magnetic and electrical stimulation of peripheral nerves. Muscle and Nerve, 1990, 13, 957-963.	2.2	84
18	Association Between Thoracic Spinal Cord Gray Matter Atrophy and Disability in Multiple Sclerosis. JAMA Neurology, 2015, 72, 897.	9.0	78

#	Article	IF	Citations
19	Disease-modifying therapy in multiple sclerosis. Neurology, 2008, 71, S8-13.	1.1	71
20	Patient centered decision making: Use of conjoint analysis to determine riskâ€"benefit trade-offs for preference sensitive treatment choices. Journal of the Neurological Sciences, 2014, 344, 80-87.	0.6	64
21	Patient Preferences for Attributes of Multiple Sclerosis Disease-Modifying Therapies. International Journal of MS Care, 2015, 17, 74-82.	1.0	64
22	A comparative analysis of Patient-Reported Expanded Disability Status Scale tools. Multiple Sclerosis Journal, 2016, 22, 1349-1358.	3.0	54
23	A questionnaire to assess neurological impairment in multiple sclerosis. Multiple Sclerosis Journal, 1998, 4, 444-451.	3.0	49
24	Glucocorticoid treatment of multiple sclerosis. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2014, 122, 455-464.	1.8	47
25	Perils and Pitfalls in the Interpretation of Clinical Trials: A Reflection on the Recent Experience in Multiple Sclerosis. Neuroepidemiology, 1999, 18, 53-63.	2.3	45
26	Spinal Cord Atrophy Predicts Progressive Disease in Relapsing Multiple Sclerosis. Annals of Neurology, 2022, 91, 268-281.	5.3	39
27	Cause of death in MS: long-term follow-up of a randomised cohort, 21â€...years after the start of the pivotal IFNÎ²-1b study. BMJ Open, 2012, 2, e001972.	1.9	37
28	Relapses in multiple sclerosis: Relationship to disability. Multiple Sclerosis and Related Disorders, 2016, 6, 10-20.	2.0	36
29	Long-term follow-up of the original interferon-Î²1b trial in multiple sclerosis: Design and lessons from a 16-year observational study. Clinical Therapeutics, 2009, 31, 1724-1736.	2.5	35
30	Establishing Long-Term Efficacy in Chronic Disease: Use of Recursive Partitioning and Propensity Score Adjustment to Estimate Outcome in MS. PLoS ONE, 2011, 6, e22444.	2.5	34
31	Causes of Death among Commercially Insured Multiple Sclerosis Patients in the United States. PLoS ONE, 2014, 9, e105207.	2.5	34
32	Neutralizing antibodies to interferon beta-1b multiple sclerosis: a clinico-radiographic paradox in the BEYOND trial. Multiple Sclerosis Journal, 2012, 18, 181-195.	3.0	33
33	The nature of genetic and environmental susceptibility to multiple sclerosis. PLoS ONE, 2021, 16, e0246157.	2.5	29
34	Comparing the efficacy of disease-modifying therapies in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2017, 18, 109-116.	2.0	25
35	Interferon-?? Therapy in Multiple Sclerosis. Drugs, 2001, 61, 1693-1703.	10.9	23
36	Predictive validity of NEDA in the 16- and 21-year follow-up from the pivotal trial of interferon beta-1b. Multiple Sclerosis Journal, 2019, 25, 837-847.	3.0	23

#	Article	IF	Citations
37	Subclasses of eventâ€related potentials: Responseâ€locked and stimulusâ€locked components. Annals of Neurology, 1986, 20, 603-609.	5.3	22
38	Haplotype-based approach to known MS-associated regions increases the amount of explained risk. Journal of Medical Genetics, 2015, 52, 587-594.	3.2	22
39	Harnessing electronic medical records to advance research on multiple sclerosis. Multiple Sclerosis Journal, 2019, 25, 408-418.	3.0	21
40	Highly conserved extended haplotypes of the major histocompatibility complex and their relationship to multiple sclerosis susceptibility. PLoS ONE, 2018, 13, e0190043.	2.5	20
41	The genetic basis of multiple sclerosis: a model for MS susceptibility. BMC Neurology, 2010, 10, 101.	1.8	19
42	Neurite Orientation Dispersion and Density Imaging for Assessing Acute Inflammation and Lesion Evolution in MS. American Journal of Neuroradiology, 2020, 41, 2219-2226.	2.4	14
43	The nature of genetic susceptibility to multiple sclerosis: constraining the possibilities. BMC Neurology, 2016, 16, 56.	1.8	13
44	Effects of different sensory inputs on the median-derived somatosensory evoked potential. Muscle and Nerve, 1989, 12, 598-603.	2.2	12
45	Therapeutic developments in multiple sclerosis. Expert Opinion on Investigational Drugs, 2000, 9, 655-670.	4.1	12
46	Marijuana and multiple sclerosis. Lancet Neurology, The, 2004, 3, 79-80.	10.2	12
47	The Genetic and Environmental Bases of Complex Human-Disease: Extending the Utility of Twin-Studies. PLoS ONE, 2012, 7, e47875.	2.5	12
48	Disease-modifying therapy in MS: a critical review of the literature. Journal of Neurology, 2004, 251, v3-v11.	3.6	11
49	Disease-modifying therapy in MS: a critical review of the literature. Journal of Neurology, 2004, 251, v50-v56.	3.6	11
50	Treatment With Interferon Beta for Multiple Sclerosis. JAMA - Journal of the American Medical Association, 2012, 308, 1627.	7.4	10
51	Single Nucleotide Polymorphism (SNP)-Strings: An Alternative Method for Assessing Genetic Associations. PLoS ONE, 2014, 9, e90034.	2.5	10
52	Variability in detection and quantification of interferon Î²-1bâ€"induced neutralizing antibodies. Journal of Neuroinflammation, 2012, 9, 129.	7.2	9
53	The Use of Interferon Beta and Glatiramer Acetate in Multiple Sclerosis. Seminars in Neurology, 2013, 33, 013-025.	1.4	9
54	An electronic, unsupervised patient-reported Expanded Disability Status Scale for multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 1432-1441.	3.0	9

#	Article	IF	Citations
55	Changes of forearm EMG and cerebral evoked potentials following sudden muscle stretch in patients with Huntington's disease. Muscle and Nerve, 1999, 22, 1557-1563.	2.2	8
56	Integrating an evidence-based assessment of benefit and risk in disease-modifying treatment of multiple sclerosis. Current Medical Research and Opinion, 2007, 23, 2823-2832.	1.9	7
57	Evidence-based medicine: promise and pitfalls. Multiple Sclerosis Journal, 2012, 18, 947-948.	3.0	7
58	The pathogenesis of multiple sclerosis. Clinical and Experimental Neuroimmunology, 2015, 6, 2-22.	1.0	6
59	Studies of the human stretch reflex. Muscle and Nerve, 2000, 23, S3-S6.	2.2	5
60	Genetic susceptibility to multiple sclerosis: interactions between conserved extended haplotypes of the MHC and other susceptibility regions. BMC Medical Genomics, 2021, 14, 183.	1.5	5
61	Genetic susceptibility to multiple sclerosis in African Americans. PLoS ONE, 2021, 16, e0254945.	2.5	5
62	The impact of warâ€stress on MS exacerbations. Annals of Neurology, 2008, 64, 114-115.	5.3	4
63	Predictors of disease activity in 857 patients with MS treated with interferon beta-1b. Journal of Neurology, 2015, 262, 2466-2471.	3.6	4
64	Order effects in response times of parkinsonian patients and normal controls. , 1999, 22, 567-572.		3
65	RELATIONSHIP BETWEEN MULTIPLE SCLEROSIS EXACERBATIONS AND STRESS: RESPONSE. Psychosomatic Medicine, 2004, 66, 288-289.	2.0	3
66	Nonrandom behavior in a reaction-time time series. Muscle and Nerve, 1996, 19, 1183-1185.	2.2	2
67	Response to GS Gronseth and E Ashman. Multiple Sclerosis Journal, 2012, 18, 1661-1662.	3.0	2
68	Reply to Tsivgoulis and colleagues comments. Multiple Sclerosis and Related Disorders, 2018, 21, 120-121.	2.0	1
69	Age at disability milestones in multiple sclerosis and history of multiple sclerosis: a unifying concept. Brain, 2006, 129, e56-e56.	7.6	0
70	Reply to â€œSpinal Cord Atrophy Is a Preclinical Marker of Progressive <scp>MS</scp>â€ Annals of Neurology, 2022, 91, 735-736.	5.3	0